Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete | ||
| Libtayo | cemiplimab | Basal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imcivree | setmelanotide | Bardet-Biedl syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
| Soliris | Eculizumab | Atypical hemolytic uremic syndrome | N/A | Complete | ||
| Ultomiris | ravulizumab | Atypical hemolytic uremic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Intuniv XR | Guanfacine hydrochloride | Attention-deficit/hyperactivity disorder (ADHD) | Do not list | Complete | ||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder, Adult | Do not list | Complete | ||
| Vyvanse | Lisdexamfetamine dimesylate | Attention deficit hyperactivity disorder | Do not list | Complete |
Last Updated : May 12, 2024